Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 6, 21–22 (1 January 2007) | doi:10.1038/nrd2227
Vorinostat
&
Abstract
Vorinostat (Zolinza; Merck) was approved by the US FDA in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. It is the first in a new class of anticancer agents that inhibit histone deacetylases, which have a key role in the epigenetic regulation of gene expression.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
